Aurobindo takes top generic spot in Portugal with €135M deal for Generis

With its €135 million deal to buy Generis Farmacêutica, India's Aurobindo gets a manufacturing plant with the capacity to make 2.2 billion tablets a year.

India’s Aurobindo Pharma, which has been building its presence around the world, has struck a new deal to buy a generics manufacturer and plant in Portugal which it says will make it the largest generics manufacturer in that country.  

Aurobindo will pay about €135 million to buy Generis Farmacêutica and a handful of subsidiaries from Magnum Capital Partners. That includes a solid-dose manufacturing facility in Amadora with the capacity to pump out about 2.2 billion tablets a year. In addition to producing for the Portuguese market, the Indian drugmaker said the new plant can be used to supplement its European production.

Generis is projected to have sales of about €64.8 million for 2016. Aurobindo projects that it can extract about €2 million in savings from its combined operations in 2018 and €5 million in 2019.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

The company has been building its manufacturing in both the EU and the U.S. In 2014 it paid $41 million to buy from Actavis seven generic drug making facilities in Western Europe including in Portugal. The deal included products, marketing authorizations and license rights as well as a long-term agreement for Aurobindo to provide Actavis with APIs. Actavis was acquired last year by Teva.

Last year, Aurobindo announced it would spend about $31.7 million to establish a U.S. headquarters in Durham, North Carolina, and to take over an existing medical plant there for manufacturing. It said it planned to add about 275 jobs at the operations.

Suggested Articles

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.

Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.  

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.